Skip to main content
ADIM logo

ADIM — Investor Relations & Filings

Ticker · 4142 ISIN · TW0004142005 LEI · 549300M5TV8YGVXU1827 TW Manufacturing
Open in API
Filings indexed 1,804 across all filing types
Latest filing 2019-07-19 Annual Report
Country TW Taiwan
Listing TW 4142

About ADIM

http://www.adimmune.com.tw/

ADIMMUNE CORPORATION, established in 1965, specializes in the research, development, and large-scale manufacturing of human vaccines and biologics. The company is a primary supplier of seasonal influenza and tetanus vaccines, maintaining production facilities that adhere to PIC/S GMP, US FDA, and EU standards. Its operations encompass the full product lifecycle, from initial R&D to commercial distribution. In addition to its proprietary vaccine portfolio, the company provides Contract Development and Manufacturing Organization (CDMO) services, supporting collaborative development and global supply chains. Recognized for its technical expertise in viral and bacterial vaccine production, the organization focuses on delivering high-quality immunization solutions to international markets while leveraging its history as a pioneering vaccine laboratory.

Recent filings

Filing Released Lang Actions
107年年報及股東會資料 — 2018_4142_20190620F11.pdf
Annual Report Classification · 100% confidence The document is titled as the '107年度年報' which translates to the 'Year 107 Annual Report' (using the Taiwanese calendar year, corresponding to 2018). It contains detailed sections typical of an annual report, including a letter to shareholders, company overview, governance report, financial overview, business operations, research and development, and future plans. It also includes detailed financial data, management discussion, and corporate governance information. The length of the document (15,000 characters) and the comprehensive content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2019-07-19 Chinese
107年年報及股東會資料 — 2019_4142_20190620F05.pdf
Regulatory Filings
2019-07-19 Chinese
107年年報及股東會資料 — 2019_4142_20190620F14.pdf
Regulatory Filings Classification · 95% confidence The document is a detailed procedural guideline from a company named 國光生物科技股份有限公司 regarding the acquisition and disposal of assets. It extensively references regulatory requirements such as the Securities Exchange Act, specifies procedures for asset transactions including securities, real estate, equipment, intangible assets, and derivatives, and outlines responsibilities, evaluation methods, and disclosure obligations. It also includes detailed rules on related party transactions, valuation reports, and reporting to regulatory authorities. The content is procedural and regulatory in nature, focusing on compliance and internal controls rather than presenting financial results or announcements. It does not contain financial statements, earnings data, or meeting results. It is not a report of financial performance, nor an announcement of voting or capital changes. It is a regulatory compliance document outlining internal processes and controls for asset transactions, consistent with a Regulatory Filing (RNS) category, which serves as a fallback for miscellaneous regulatory and compliance documents that do not fit other specific categories.
2019-07-19 Chinese
107年年報及股東會資料 — 2019_4142_20190620F17.pdf
Major Shareholding Notification Classification · 95% confidence The document lists the top ten shareholders and their shareholding percentages, along with relationships among them. It is a detailed disclosure of major shareholding information, including names, share counts, and relationships. There is no indication of it being a full annual or interim report, audit report, or other types of filings. This matches the definition of a Major Shareholding Notification, which reports changes or details about significant share ownership levels.
2019-07-19 Chinese
107年年報及股東會資料 — 2018_4142_20190620F04.pdf
Annual Report Classification · 100% confidence The document is titled as the '107年度年報' which translates to the 'Annual Report for the year 107' (in the Taiwanese calendar, year 107 corresponds to 2018). It contains detailed sections typical of an annual report, including a letter to shareholders, company overview, governance report, financial overview, business operations, research and development, and future plans. It also includes detailed financial data, auditor information, and comprehensive company information. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2019-07-19 Chinese
107年年報及股東會資料 — 2019_4142_20190620F02.pdf
AGM Information Classification · 95% confidence The document is titled as a shareholder meeting manual for the 108th Annual General Meeting (AGM) of a company, with detailed agenda items including reports, approvals, discussions, and elections. It contains extensive materials such as the 107th fiscal year business report, audit committee review report, financial statements audited by certified accountants, loss compensation table, amendments to asset acquisition and disposal procedures, and lists of director candidates. The document includes detailed financial data, management reports, and governance-related materials presented at the AGM. The presence of the full business report, audited financial statements, and other comprehensive reports indicates this is the actual AGM Information document, not just an announcement or proxy statement. Therefore, the document fits the category of AGM Information (AGM-R).
2019-07-19 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.